Skip to main content

Testing AI Medicine Recognition for Indian Clinic Workflows

Evaluate AI medicine recognition from the source through catalogue matching, clinician review and the final prescription format. Compare complete entries, including stated strength, form, release details and context; report omissions and unsupported additions separately. A familiar brand name or high field-accuracy score cannot establish correct prescribing, and a clinician’s correction must not be counted as an unassisted AI success.

By Bractis · Updated · 14 min read

Indian doctors assessing AI scribes, prescription OCR and medicine-catalogue matching, with a focus on documentation fidelity rather than treatment recommendations.

Define the medicine task before comparing accuracy claims

Recognizing what a doctor said is different from choosing what a patient should take. Extracting a name from an old prescription is different from confirming current use. Mapping an entry to a catalogue is different again. A vendor demonstration can blur these tasks by showing a clean prescription at the end without revealing where the medicine details came from.

Ask the vendor to identify each transformation: speech or image to text, text to medicine candidate, candidate to catalogue entry, and entry to patient-facing instruction. Inspect the intermediate result where available. If a strength was never supplied, a system that fills one has made an additional selection; it has not merely transcribed the source.

This guide evaluates documentation and matching. It does not recommend medicines, doses, substitutions or indications. A local recognition trial is not regulatory validation or evidence that an AI system can prescribe independently.

Treat a medicine entry as several linked details

The name is only one element. A correct-looking brand with the wrong formulation can still represent a different entry. Combination products require checking all stated components and their relationship, while a release qualifier may distinguish entries that otherwise look similar. Do not reduce the reference to a single text label if the destination contains more fields.

WHO’s publication on look-alike and sound-alike medicines describes confusion involving similar names, including brand and generic names. That provides context for deliberate near-name testing; it does not supply an accuracy score for any AI product or a ready-made Indian clinic benchmark.

Have an appropriately qualified reviewer prepare the expected entries from reliable product information and the intended fictional source. Record the reference and its date. Search suggestions, a model’s own answer and an unreviewed marketplace listing should not become the ground truth simply because they are easy to obtain.

On a narrow screen, scroll the table horizontally to read all columns.

Fields to compare for each medicine recognition case
ElementComparison questionFailure to record
Name and stated identityDoes the entry match the source rather than a similar candidate?Wrong brand, ingredient or unsupported substitution
Strength and unitsAre the stated values and units preserved?Missing, changed or invented strength
Form and release detailsDoes the selected formulation match what was specified?Default form or lost release qualifier
Combination componentsAre all specified components represented correctly?Dropped component or wrong association
Instructions and statusAre source instructions and historical/current status preserved?Invented instruction or old prescription made current

Source: WHO: Medication safety for look-alike, sound-alike medicines

Build a case panel around the clinic’s actual work

Select medicines and source types relevant to the clinic’s permitted evaluation scope, then create fictional dictations or documents. Include routine items, similar-looking names, more than one formulation, combination entries and deliberately incomplete information. Do not publish a list of confusing real names as if it were a prescribing guide; the local reference should be reviewed and controlled.

Separate normal-use cases from deliberate stress cases. A noisy recording and an illegible scan help expose failure behavior, but their frequency in a test pack does not establish their frequency in everyday work. Record why each case exists so the final report does not turn a deliberately difficult panel into a claimed real-world error rate.

Include the language mixture and devices the doctors actually use. Run the same reference through transcription and final field mapping when the product supports both. If the spoken name is recognized correctly but the catalogue chooses a different formulation, the correction belongs to the mapping stage rather than the speech model alone.

Test what happens when the source is incomplete

An incomplete medicine entry should remain visibly incomplete until the responsible clinician resolves it. Include fictional cases where the name is unclear, the strength is absent or the formulation is unspecified. Inspect whether the system asks for review, leaves a gap or confidently selects the most common catalogue option.

A useful abstention is distinct from a correct complete answer and from a wrong confident answer. It creates review work but preserves the lack of evidence. Do not penalize every blank as if it were worse than a plausible guess; decide how the interface helps the doctor resolve it and prevents premature issuing.

Also test a corrected dictation: the clinician retracts one candidate and states another. Verify the final note, medicine panel and preview. The first candidate should not remain hidden in a structured field merely because the visible transcript contains the correction.

Build cases that identify which medicine-processing step failed

A useful Indian-clinic evaluation includes the way the doctor identifies an item: a familiar brand in mixed-language speech, a generic description, an outside prescription or a catalogue search. Keep the expected identity tied to the source. A catalogue’s preferred display name may differ from the spoken label without being wrong, but that is acceptable only when the reviewed identity and all relevant details agree.

The following casebook uses fabricated labels and catalogue references. Test Product P, Component A, Component B and Strength S are placeholders, not medicine names, ingredients or dosing instructions. A clinic would prepare its own controlled references with a suitably qualified reviewer. The purpose is to distinguish recognition, mapping and clinical-status errors without publishing an unreviewed list of real products.

For M-03, the transcript may preserve a modified-release qualifier while the catalogue highlights an immediate-release candidate with a similar name. That is not evidence that the two entries are interchangeable. The reviewer should inspect the selected identity and the lost qualifier. Making the transcription more accurate will not by itself repair a catalogue-selection rule that ignores formulation.

For M-04, deliberately leave the strength absent in the source. The expected result is an explicit unresolved detail, not whichever strength appears most often in the catalogue. Record whether the uncertainty remains visible in the medicine panel and final preview. A model that guesses correctly by chance in one test still has not established a reliable rule for absent information.

These cases also make support reports more useful. Describe the first observed divergence, the reference identity and the affected destination. A screenshot of the final wrong name alone cannot show whether the source was unclear, the recognizer changed it or a later mapping step replaced it. Use fictional reproductions rather than sending patient prescriptions in an unrestricted ticket.

On a narrow screen, scroll the table horizontally to read all columns.

Original medicine casebook: locate the first observed divergence
Fictional source and caseObserved proposalWhat the evaluation must distinguish
M-03: Test Product P; modified-release explicitly specifiedTranscript retains qualifier; selected catalogue item is immediate-releaseRecognition succeeded for the qualifier; catalogue mapping did not preserve it
M-04: item identity stated; strength deliberately absentStrength S appears from a catalogue defaultUnsupported completion, even if the default looks familiar
M-05: a combination explicitly contains Components A and BCandidate contains A onlyPartial component recognition is not a correct complete entry
M-06: an old prescription is uploaded as historyExtracted item enters a new prescription draft automaticallyHistorical extraction has crossed into a different clinical task

Report denominators that reveal the important errors

Ask whether a claimed percentage measures words, medicine mentions, individual fields or completely correct entries. These are not interchangeable. A long note contains many easy words that can dilute a few wrong medicine details. Field-level accuracy can also look high when each entry has several correct fields and one consequential mismatch.

In an invented example, 20 medicine entries contain five assessed fields each: 100 fields. Ninety-eight fields match the reference, but two entries have an incorrect strength. The field result is 98 out of 100; only 18 of 20 entries are completely correct. Both figures need the error description. Neither is a clinical acceptability threshold.

Report missing entries, unsupported added entries and unresolved items separately. Score the generated result before doctor edits, then describe how well review detected and corrected the problems. If only the final edited prescription is scored, the report can hide the burden and failures of the AI stage.

NIST’s voluntary generative-AI profile recommends empirical evaluation of capability claims and cautions against extrapolating from narrow, anecdotal assessments. Use the local exercise to identify fit and failures, while requesting relevant broader evidence from the vendor.

Source: NIST AI 600-1: Generative AI risk management profile

Follow the same twenty entries through review and rendering

Extend the invented twenty-entry example into M-20, a staged evaluation with no real patient or issued prescription. Every entry has five preselected fields, and the reference supplies all five; incomplete-source cases are assessed separately. At generation, entries M-07 and M-14 each have one wrong strength. The other 18 entries match in all five fields. This produces 98 correct fields out of 100 and 18 completely correct entries out of 20.

During the fictional review, the clinician catches and repairs M-07 but misses M-14. The post-review state has 99 correct fields and 19 completely correct entries. The review detected one of the two known generated errors. Do not report the 99% field result as recognition accuracy: it includes a human correction. Do not describe review as fully effective merely because an approval action occurred.

Next, the export clips the required release qualifier from M-19, an entry that had previously been correct. In this exercise, that makes one additional assessed field wrong. The rendered copy returns to 98 correct fields and 18 completely correct entries: M-14 still has its original strength error, while M-19 has a new output defect. The final aggregate happens to equal the initial aggregate, despite a different error history.

The original two mismatches, the correction and the new export defect therefore need separate records. Compare entry identities between stages rather than subtracting aggregate percentages and assuming nothing changed. The exercise illustrates why a clinic should inspect the actual print or shared format, even after reviewing the medicine panel.

No percentage here is a recommended acceptance threshold. A small test pack also cannot quantify the rate of errors in routine OPD work. Use its failures to decide which task remains unresolved and what evidence is needed before relying on the workflow. The test copy is held for repair; nothing in this example authorizes issuing the defective result.

On a narrow screen, scroll the table horizontally to read all columns.

M-20: the same fictional 20 entries and 100 assessed fields at three stages
StageCorrect fields / complete entriesRemaining discrepancy
Initial generated result98/100 fields; 18/20 complete entriesM-07 and M-14 each have one wrong strength
After fictional clinician review99/100 fields; 19/20 complete entriesM-07 corrected; M-14 missed
Rendered test copy98/100 fields; 18/20 complete entriesM-14 still wrong; M-19 loses a required release qualifier

Retest the changed component without losing earlier evidence

Treat a new catalogue version and a new export layout as different changes. A catalogue fix should be tested on the identity and formulation cases it could affect; an export fix should retain the accepted entry and test its representation. Changing both at once may solve the visible example while leaving the team unable to identify the cause.

Keep the reference fixed unless the reference itself was wrong. If a reviewer changes the expected medicine identity after seeing the output, record that correction and rerun the affected comparison. Otherwise the test can quietly redefine success to match the product. Separate a disputed source, a wrong reference and a wrong generated entry in the evaluation record.

For M-20, retain the initial errors as well as the missed-review and rendering cases. A later version needs to demonstrate what changed at each destination. If a previously correct entry now fails, record the regression even when the overall percentage improves. An owner can then make a bounded decision about narrative drafting, catalogue matching or output generation instead of accepting one blanket medical-AI accuracy claim.

Verify the record that will actually be issued

The doctor’s selection must survive through the final document. Inspect the prescription preview, printed output and supported sharing format with fictional data. Check for truncated qualifiers, misplaced units and text that differs from the accepted field. A correct database selection is not enough if the patient-facing representation changes its meaning.

Keep historical transcription separate from new prescribing. An imported prescription may be evidence for medication reconciliation, but it should not silently become a fresh order. Demonstrate the product’s distinction between attaching a source, accepting extracted text and issuing a new prescription.

If the tool cannot make that distinction clear, limit the evaluation scope or retain manual entry for the affected task. A purchasing decision can be specific: useful for drafting narrative history, unresolved for medicine mapping. The clinic does not need to treat the entire product as one indivisible accuracy claim.

Retest after catalogue, model or configuration changes

Record the available model or product version, catalogue version or update date, selected language and relevant settings. A later update may change candidate matching even if the interface looks identical. Keep the previously failed cases and some previously successful cases for comparison, with the same reviewed reference.

Use a designated clinician to decide the response to a material mismatch. The response may include correcting the case, restricting a workflow, requesting vendor clarification and retesting. A small panel with no observed errors does not prove that future use will be error-free, especially across untested specialties or medicines.

The following record makes the trial reproducible without turning it into an unsupported certification. Keep actual patient identifiers out of demonstration material and support reports.

A strong percentage conceals two wrong strengths

A fictional trial reports 98 correct fields out of 100. On inspection, two different medicine entries each contain a wrong strength. The clinic records 18 fully correct entries out of 20, describes both mismatches and tests whether review exposes them before issuing. It does not use the aggregate 98% as a safety claim or compare it with a competitor’s differently defined score.

Medicine Recognition Evaluation Worksheet

Use these prompts in your clinic’s own notes. Record the result, responsible person and next action for each item.

Task boundary
Identify exactly which recognition and mapping stages are being evaluated.
Reference quality
Prepare reviewed fictional cases with traceable product information and incomplete inputs.
Results
Report fields, complete entries, omissions, additions and unresolved results separately.
Acceptance and change
Verify final output, define permitted scope and retain cases for relevant updates.

Questions doctors ask

Should AI accuracy be measured after the doctor corrects the prescription?

Record the generated result before edits, then separately record review detection, corrections and final-output defects. A corrected entry shows work by the clinician; counting it as an unassisted AI success hides the original error and review burden.

What if the medicine name is transcribed correctly but the catalogue selects the wrong formulation?

Trace the recognized text to the selected catalogue identity and compare the stated formulation and release details. Treat it as a mapping failure where the evidence supports that finding. Correct and inspect affected outputs; do not assume a similar name permits substitution.

Is 98% accuracy enough for AI medicine documentation?

The percentage alone is insufficient. Establish the task, denominator, case coverage and nature of errors, including whether complete medicine entries and issued outputs were checked.

Does recognizing an Indian brand name verify the prescription entry?

No. Check the stated strength, formulation, combination details, instructions and context. Recognition does not authorize a prescribing decision.

Should AI fill a missing medicine strength from the catalogue?

Do not treat a default candidate as source evidence. Keep the missing detail visible for the responsible clinician to resolve.

Can a small clinic pilot validate a medical AI product?

It can expose local fit and failures within its scope. It does not establish general clinical performance, regulatory validation or accuracy on untested cases.

When should medicine-recognition tests be repeated?

Repeat relevant cases after changes that may affect recognition or mapping, such as model, catalogue, language or configuration updates, and after a material failure.

Sources and scope

Updated on . All numerical examples are invented to explain evaluation. No medicine, dose, clinical accuracy threshold or autonomous prescribing capability is recommended. No independent clinical or legal review is claimed.

Try the workflow
with Bractis.

Trace a fictional medicine from source to catalogue to final output, including an absent strength and a corrected dictation, and report complete-entry results.

Request a clinic demo